Educaton Steering Committee
Deborah K. Armstrong, MD, Speaker
Johns Hopkins Kimmel Cancer Center
Johns Hopkins University School of Medicine
Judith K. Wolf, MD
Department of Gynecologic Oncology University of Texas
M.D. Anderson Cancer Center
John K. Chan, MD
Assistant Professor and Chief
Department of Gynecologic Oncology
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Paul A. DiSilvestro, MD
Dept of Obstetrics and Gynecology
Program in Women’s Oncology
Bradley J. Monk, MD
Dept of Obstetrics and Gynecology
University of California, Irvine
UCI Medical Center
James T. Thigpen, MD
Professor of Medicine
Dept of Internal Medicine
University of Mississippi Medical Center
Ovarian cancer is the most common cause of death from gynecologic malignancies and remains the fifth leading cause of cancer death in women in the United States. Because early disease is difficult to detect, women are often not diagnosed with ovarian cancer until the disease has progressed to advanced stages, which are associated with poor prognosis and a high risk for disease relapse. After first-line treatment, the rate of relapse in women with ovarian cancer stage III-IV low volume residual disease (tumors all <2 cm in size) is 60 to 70 percent, and in stage III-IV large volume residual, it is 80 to 85 percent.
This online release of a CME/CE Grand Rounds program presented at Lehigh Valley Hospital in Allentown, PA on July 25, 2008 is designed to enhance the knowledge and understanding of recent advancements in the treatment of patients with recurrent ovarian cancer. Our expert faculty will discuss the currently available therapeutic agents for recurrent ovarian cancer, the risk/benefits of combination therapy, and second-line chemotherapy for platinum-sensitive and platinum-resistant disease. The discussion will center on case studies designed to emphasize the importance of establishing individualized treatment plans for each patient. Program Developer/Facilitator
. Target Audience
This activity, which was developed by experts in ovarian cancer treatment, has been developed for gynecologic oncologists, medical oncologists, and nurses involved in the treatment of patients with ovarian cancer.
Upon completion of this educational activity, the participant should be able to:
Describe optimal chemotherapy regimens for patients who develop platinum-sensitive recurrent ovarian cancer.
Describe optimal chemotherapy regimens for patients who develop platinum-resistant recurrent ovarian cancer.
Outline methods to detect recurrent disease and monitor treatment response, including measuring CA-125 levels and following serial imaging studies.
Explore the role of emerging agents in the treatment of recurrent ovarian cancer.
In meeting the requirements of full disclosure and in compliance with the ACCME and ANCC Standards for Commercial Support, the Education Steering Committee has provided the following information regarding potential conflicts of interest. It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
This educational activity may contain discussion of published and/or investigational uses of oncology agents. Some uses may not have been approved by the FDA. The faculty have agreed to disclose discussion of off-label use during their presentations. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Deborah K. Armstrong, MD discloses that she is a memeber of advisory committees for Bayer/Onyx, Biogen Idec, Cephalon, Genentech, and TriPath.
John K. Chan, MD discloses that he is a member of s speakers' bureau for Ortho Biotech.
Paul A. DiSilvestro, MD discloses that he is a member of s speakers' bureau for Merck & Co.
Bradley J. Monk, MD discloses that he is a member of s speakers' bureaus for Eli Lilly and Company, GlaxoSmithKline, and Ortho Biotech.
James T. Thigpen, MD discloses that he is a consultant for Berlex, Bionumerik Pharmaceuticals, Bristol-Myers Squibb, Celgene, Cell Therapeutics, Eli Lilly and Company, EMD Biosciences, Genentech, GlaxoSmithKline, McNeil Pharmaceutical, Novartis, Ortho Biotech, sanofi-aventis, and Telik.
Judith K. Wolf, MD discloses that she is a member of speakers' bureaus for Eli Lilly and Company, GlaxoSmithKline, Merck & Co., Ortho Biotech. Credit Statements
Physicians: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media.
AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians. AKH Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurses: AKH Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
AKH Inc. designates this educational activity for 1.0 contact hour (0.1 CEU).
Credit is awarded to participants who complete an online evaluation and score 70% or better on the post-test. One retake is allowed. A statement of credit can be printed following successful completion. This activity should take approximately 60 minutes to complete. Commercial Support Statements
Funded by an educational grant from Ortho Biotech.
Please turn off all pop-up blockers to assure access to the educational activity.
Click on the "Start program" icon at the bottom of this screen. If you are not already logged in to the site, this will bring you to the login/registration page where you will be able to register as a new cmecorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
The next main menu screen will permit you to check for or download the Flash player required to run this program. Clicking on "Click here to start the Virtual Meeting" on this screen will begin the program presentation. The menu at the top of the presentation screen will allow you to view the question and answer segment, the reference list, and the CME/CE post-test and evaluation. The program will take approximately 60 minutes to complete.
Upon completion of the program, click on the post-test button to register and/or access the post-test and program evaluation.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME/CE certificate.
©2008, Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this activity are those of the presenter and do not necessarily reflect the opinions or recommendations of her affiliated institutions, the publisher, AKH Inc., or Ortho Biotech. Any medications or other diagnostic or treatment procedures discussed by the program faculty should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or risks, and without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.